Proclara Biosciences has been developing the General Amyloid Interaction Motif (GAIM), a broad tool that the company hopes will disrupt existing amyloid aggregates and halt their spread. GAIM has been in development for a number of years thanks in part to support from the Michael J Fox Foundation.
Unfortunately the company reported on August 15, 2019, their phase 1B study was concluded and the news was not positive. While this was not an efficacy trial, the drug did not seem to be efficacious. There has been no public activity from Proclara since 2019 though the company is still listed as being active according to Crunchbase.